BRPI1013777A8 - Compostos agonistas do receptor 5-ht4 para tratamento de distúrbios cognitivos. - Google Patents

Compostos agonistas do receptor 5-ht4 para tratamento de distúrbios cognitivos.

Info

Publication number
BRPI1013777A8
BRPI1013777A8 BRPI1013777A BRPI1013777A BRPI1013777A8 BR PI1013777 A8 BRPI1013777 A8 BR PI1013777A8 BR PI1013777 A BRPI1013777 A BR PI1013777A BR PI1013777 A BRPI1013777 A BR PI1013777A BR PI1013777 A8 BRPI1013777 A8 BR PI1013777A8
Authority
BR
Brazil
Prior art keywords
treatment
cognitive disorders
receptor agonist
agonist compounds
compounds
Prior art date
Application number
BRPI1013777A
Other languages
English (en)
Inventor
Beattie David
Shen Fei
A M Smith Jacqueline
Murray Mc Robert
Chang Ray
Original Assignee
Theravance Biopharma R&D Ip Llc
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc, Theravance Inc filed Critical Theravance Biopharma R&D Ip Llc
Publication of BRPI1013777A2 publication Critical patent/BRPI1013777A2/pt
Publication of BRPI1013777A8 publication Critical patent/BRPI1013777A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSTOS AGONISTAS DO RECEPTOR 5-HT4 PARA TRATAMENTO DE DISTÚRBIOS COGNITIVOS. A invenção está relacionada ao uso de compostos agonistas de receptor 5-HT, específicos para o tratamento de distúrbios cognitivos, em particular, ao uso desses compostos em combinação com outros agentes, especificamente inibidores de acetilcolinesterase, para o tratamento de doença de Alzheimer e de outros distúrbios cognitivos.
BRPI1013777A 2009-04-13 2010-04-12 Compostos agonistas do receptor 5-ht4 para tratamento de distúrbios cognitivos. BRPI1013777A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16874109P 2009-04-13 2009-04-13
US29255910P 2010-01-06 2010-01-06
PCT/US2010/030760 WO2010120695A2 (en) 2009-04-13 2010-04-12 5-ht4 receptor agonist compounds for treatment of cognitive disorders

Publications (2)

Publication Number Publication Date
BRPI1013777A2 BRPI1013777A2 (pt) 2016-04-05
BRPI1013777A8 true BRPI1013777A8 (pt) 2017-09-19

Family

ID=42237213

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013777A BRPI1013777A8 (pt) 2009-04-13 2010-04-12 Compostos agonistas do receptor 5-ht4 para tratamento de distúrbios cognitivos.

Country Status (23)

Country Link
US (2) US8404711B2 (pt)
EP (1) EP2419104B1 (pt)
JP (1) JP2012523437A (pt)
KR (1) KR20120017421A (pt)
CN (2) CN102395371A (pt)
AU (1) AU2010236734B2 (pt)
BR (1) BRPI1013777A8 (pt)
CA (1) CA2758321A1 (pt)
CY (1) CY1119800T1 (pt)
DK (1) DK2419104T3 (pt)
ES (1) ES2654930T3 (pt)
HR (1) HRP20180018T1 (pt)
HU (1) HUE038141T2 (pt)
IL (1) IL215660A0 (pt)
LT (1) LT2419104T (pt)
MX (1) MX2011010782A (pt)
NO (1) NO2419104T3 (pt)
PL (1) PL2419104T3 (pt)
PT (1) PT2419104T (pt)
RU (1) RU2569056C2 (pt)
SI (1) SI2419104T1 (pt)
WO (1) WO2010120695A2 (pt)
ZA (1) ZA201107490B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
KR20180011888A (ko) 2008-11-19 2018-02-02 포럼 파마슈티칼즈 인크. (ｒ)-７-클로로-ｎ-(퀴누클리딘-３-일)벤조［ｂ］티오펜-２-카르복사미드 및 그 약학적으로 허용가능한 염을 이용한 인지 장애의 치료
BRPI1014793A2 (pt) * 2009-05-11 2016-04-05 Envivo Pharmaceuticals Inc tratamento de distúrbios de cognição com determinados receptores de ácido alfa-7-nicotínico em combinação com inibidores de acetil-colinesterase
RS54742B1 (sr) 2010-05-17 2016-10-31 Forum Pharmaceuticals Inc Kristalni oblik (r)-7-hlor-n-(hinuklidin-3-il)benzo[b]tiofen-2-karboksamid hidrohlorid monohidrata
WO2013169646A1 (en) 2012-05-08 2013-11-14 Envivo Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
US20150306158A1 (en) 2012-08-16 2015-10-29 University-Industry Cooperation Group Of Kyung Hee University Lactic acid bacteria capable of preventing and/or treating senescence and dementia
US10874701B2 (en) 2012-08-16 2020-12-29 University-Industry Cooperation Group Of Kyung Hee University Lactic acid bacteria capable of preventing and/or treating senescence and dementia
PT3630098T (pt) 2017-05-24 2021-04-21 H Lundbeck As Combinação de um antagonista do receptor 5-ht6 e de um inibidor de acetilcolinesterase para utilização no tratamento da doença de alzheimer numa subpopulação de pacientes portadores de alelos apoe4
US11484502B2 (en) 2017-06-01 2022-11-01 Eisai R&D Management Co., Ltd. Pharmaceutical composition comprising PDE9 inhibitor
JP7282028B2 (ja) 2017-06-02 2023-05-26 富士フイルム富山化学株式会社 脳萎縮予防または治療剤
CA3069989A1 (en) 2017-07-31 2019-02-07 Theravance Biopharma R&D Ip, Llc Methods of treating symptoms of gastroparesis using velusetrag

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE345803T1 (de) * 2000-03-03 2006-12-15 Eisai Co Ltd Neue methoden unter verwendung von cholinesteraseinhibitoren
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7598265B2 (en) 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists

Also Published As

Publication number Publication date
AU2010236734A8 (en) 2012-02-16
AU2010236734A1 (en) 2011-11-03
NO2419104T3 (pt) 2018-04-07
MX2011010782A (es) 2012-01-20
JP2012523437A (ja) 2012-10-04
CN102395371A (zh) 2012-03-28
LT2419104T (lt) 2018-02-12
RU2569056C2 (ru) 2015-11-20
IL215660A0 (en) 2012-01-31
EP2419104A2 (en) 2012-02-22
CA2758321A1 (en) 2010-10-21
EP2419104B1 (en) 2017-11-08
HRP20180018T1 (hr) 2018-02-09
US20140057939A1 (en) 2014-02-27
DK2419104T3 (en) 2018-02-05
KR20120017421A (ko) 2012-02-28
ES2654930T3 (es) 2018-02-15
AU2010236734B2 (en) 2015-06-11
US8404711B2 (en) 2013-03-26
HUE038141T2 (hu) 2018-10-29
CN105832735A (zh) 2016-08-10
ZA201107490B (en) 2012-06-27
SI2419104T1 (en) 2018-03-30
RU2011146032A (ru) 2013-05-20
CY1119800T1 (el) 2018-06-27
PT2419104T (pt) 2018-01-31
BRPI1013777A2 (pt) 2016-04-05
PL2419104T3 (pl) 2018-04-30
WO2010120695A3 (en) 2010-12-02
US20100261752A1 (en) 2010-10-14
WO2010120695A2 (en) 2010-10-21

Similar Documents

Publication Publication Date Title
BRPI1013777A8 (pt) Compostos agonistas do receptor 5-ht4 para tratamento de distúrbios cognitivos.
EA201071291A3 (ru) Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
MX2009006304A (es) Nuevos compuestos de oxadiazol.
CY1113734T1 (el) Χημικες ενωσεις
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
ATE469895T1 (de) Cgrp-rezeptorantagonisten
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
MY155317A (en) Benzene sulfonamide thiazole and oxazole compounds
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
IL193080A0 (en) Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith
MX2010005031A (es) Anticuerpos de axl.
CL2007001451A1 (es) Compuestos derivados de [1,2,3]-tiazol-4-ilmetoxilo, agonista del receptor farnesoide x (fxr); composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar dislipidemia y enfermedades relacionadas.
EA201171063A1 (ru) Фармацевтические составы олмесартана
MY169479A (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
MY147649A (en) Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
BRPI0919231A2 (pt) agonista de receptor de neuropeptídeo-2, composição farmacêutica que o compreende, seu uso e método para o tratamento ou profilaxia de enfermidades
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
BR112013009004A2 (pt) combinações de agonistas de receptor de serotonina para o tratamento de distúrbios de movimento
MY143269A (en) Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder
BR112014000634A2 (pt) métodos para tratamento de incontinência associada com atividade sexual
MX2010000956A (es) Derivados de isoftalamida que inhiben actividad de beta-secretasa.
EA200802104A1 (ru) Применение композиций, содержащих антагонисты каппа-опиоидных рецепторов, для лечения диссоциативных расстройств

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: THERAVANCE BIOPHARMA RANDD IP, LLC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]